Skip to content
Screener

Neuropace, Inc. NPCE Q1 2025 earnings

Reported May 13, 2025 · Before market open

Revenue$22.5MMiss by $186.3K
EPS-$0.21Beat by $0.05
Revenue estimate$22.7M
EPS estimate-$0.26

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$27.1M
EPS estimate-$0.11

Financials

Q1 2025

Income statement

See full
Revenue$22.5M+24.3%
Gross profit$17.3M+30.0%
Operating income-$5.1M+31.8%
Net income-$6.6M+26.2%
EPS (diluted)-$0.21+34.4%

Balance sheet

See full
Cash & equivalents$27.1M+107%
Total debt$73.2M+0.1%
Total equity$24.3M+69.2%
Total assets$110.2M+11.5%

Cash flow

See full
Operating cash flow-$7.5M+0.6%
CapEx$37.0K-64.4%
Free cash flow-$7.5M+1.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$400.16M+13.1%
Enterprise value$446.17M+7.8%
P/S4.7×-0.4×

Profitability

See full
Gross margin74.8%+0.9pp
Operating margin-22.9%-6.6pp
Net margin-29.4%-7.7pp
FCF margin-21.5%-3.0pp

Returns & leverage

See full
Return on equity-128.5%-16.5pp
Debt / equity3×-2.1×
Current ratio6.6×+0.2×

FAQ

When did Neuropace, Inc. report Q1 2025 earnings?
Neuropace, Inc. (NPCE) reported Q1 2025 earnings on May 13, 2025 before market open.
What were Neuropace, Inc.'s Q1 2025 revenue and EPS?
Neuropace, Inc. reported revenue of $22.5M and eps of $-0.21 for Q1 2025.
Did Neuropace, Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $22.7M by $186.3K. EPS beat the consensus estimate of $-0.26 by $0.05.
How did Neuropace, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 24.3% from $18.1M a year earlier and eps grew 34.4% from $-0.32.
Where can I find Neuropace, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001528287-25-000012) and the 10-Q periodic report (0001528287-25-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.